Compare CVS Health Corp (CVS) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

VYMI trades at $105.05, up 0.64% on the day, near its 52-week high with a bullish technical signal. The ETF offers a 3.4% dividend yield and has delivered strong returns, outperforming the S&P 500 with a 55% total return since last coverage. Recent institutional buying and positive media coverage highlight growing investor interest in its international high-dividend strategy.

Outlook remains positive due to diversification benefits and dividend growth, but risks include currency fluctuations and global economic volatility. Analysts favor its yield and growth potential, though overbought RSI levels suggest near-term consolidation may occur.